Cybin announces grant of additional u.s. patent in support of its cyb003 deuterated psilocybin analog program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the united states patent and trademark office (“uspto”) has granted u.s. patent 11,834,410 in support of its cyb003 program. the patent, which is expected to provide exclusivity until at least 2041, includ.
CYBN Ratings Summary
CYBN Quant Ranking